DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9.220,785 B2 Adami Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9.220,785 B2 Adami Et Al US009220785B2 (12) United States Patent (10) Patent No.: US 9.220,785 B2 Adami et al. (45) Date of Patent: Dec. 29, 2015 (54) LIPOPEPTIDES FOR DELIVERY OF 47/48323 (2013.01); A61 K48/0033 (2013.01); NUCLECACDS A61K 48/004I (2013.01); C07K 14/00 (2013.01); C12N 15/87 (2013.01); A61 K48/00 (71) Applicant: Marina Biotech, Inc., Bothell, WA (US) (2013.01) (72) Inventors: Roger C. Adami. Bothell, WA (US); (58)58) tField OSSOof Classification SearchSea Militigrists See application file for complete search history. WA (US) (56) References Cited (73) Assignee: Marina Biotech, Inc., Bothell, WA (US) U.S. PATENT DOCUMENTS (*) Notice: Subject to any distic the t 6,713,078 B2 * 3/2004 Lehrer et al. .................. 424/405 patent 1s extended or adjusted under 2006/0272049 A1* 11/2006 Waterhouse et al. ......... 800,279 U.S.C. 154(b) by 0 days. 2007/01293.05 A1 6/2007 Divita et al. .................... 514f13 (21) Appl. No.: 13/715,768 FOREIGN PATENT DOCUMENTS (22) Filed: Dec. 14, 2012 WO WOO198362 A2 * 12/2001 WO WO 200709965.0 A1 * 9, 2007 (65) Prior Publication Data WO WO 2008049078 A1 * 4, 2008 US 2013/0231382 A1 Sep. 5, 2013 * cited by examiner Related U.S. Application Data Primary Examiner — Jeffrey E. Russel (63) Continuation of application No. 12/750,622, filed on (74) Attorney, Agent, or Firm — Eckman Basu LLP Mar. 30, 2010, now abandoned, which is a continuation of application No. PCT/US2008/078627, (57) ABSTRACT filed on Oct. 2, 2008. (60) Provisional application No. 60/976,894, filed on Oct Lipopeptide compounds with a central peptide and having 2, 2007 pp sy--- is lipophilic groups attached at each terminus, and salts and uses s thereof. The lipophilic groups can be derived from a natu (51) Int. Cl rally-occurring lipid, or can be a C(1-22)alkyl, C(6-12)cy A6 IK 47/42 (2006.01) cloalkyl, C(6-12)cycloalkyl-alkyl, C(3-18)alkenyl, C(3-18) C07K I4/00 (2006.01) alkynyl, C(1-5)alkoxy-C(1-5)alkyl, or a sphinganine, or (2R, A6 IK 4.8/00 (2006.015 3R)-2-amino-1,3-octadecanediol, icosasphinganine, A6 IK 47/48 (2006.015 sphingosine, phytosphingosine, cis-4-sphingenine. The com CI2N 15/87 (200 6. 01) pounds can be used in compositions to deliver active agents to (52) U.S. Cl cells, including interfering-RNA agents and antisense RNAS. CPC ........... A61K 47/42 (2013.01); A61K 47/48046 (2013.01); A61 K47/48053 (2013.01); A61 K 11 Claims, No Drawings US 9.220,785 B2 1. 2 LIPOPEPTIDES FOR DELVERY OF Moreover, there is a need for compositions and methods for NUCLECACDS delivery of interfering RNAs to selected cells, tissues, or compartments to modulate gene expression in a manner that SEQUENCE LISTING will alter a phenotype or disease state. This application includes a Sequence Listing Submitted BRIEF SUMMARY herewith via EFS-Web as an ASCII file created on Apr. 2, 2013, named MDR-07-23USB1 SeqList corrected.TXT, This invention satisfies these needs and fulfills additional which is 130,036 bytes in size, and is hereby incorporated by objects and advantages by providing a range of novel com reference in its entirety. 10 pounds, compositions, formulations and methods that employ an interfering nucleic acid or precursor thereof in FIELD OF THE INVENTION combination with various components including lipopep tides, lipids, and natural or synthetic polymers. This invention relates to novel drug delivery enhancing In some embodiments, this invention includes a peptide agents including lipids that are useful for delivering various 15 having 2 to 100 amino acid residues and a lipophilic group molecules to cells. This invention provides a range of com attached to at least one terminus of the peptide, or to at least pounds, compositions, formulations, methods and uses of one amino acid residue, and salts and uses thereof. The lipo Such agents directed ultimately toward drug delivery, thera philic group may be attached to the N-terminus, C-terminus peutics, and the diagnosis and treatment of diseases and con or both termini of the peptide. The lipophilic group may be ditions, including those that respond to modulation of gene attached to at least one interal amino acid residue (i.e., an expression or activity in a subject. More specifically, this amino acid residue that is not the N-terminus or the C-termi invention relates to compounds, liposomes, lamellar vesicles, nus amino acid residue of the peptide). The lipophilic group emulsions, micelles, Suspensions, particles, solutions and may be attached to either termini or both and at least one other forms of delivery enhancing compositions and formu internal amino acid residue. lations, as well as therapeutic methods and uses for these 25 This Summary, taken along with the detailed description of delivery materials. the invention, as well as the appended examples and claims as a whole encompasses the disclosure. BACKGROUND DETAILED DESCRIPTION The delivery of a therapeutic compound to a subject can be 30 impeded by limited ability of the compound to reach a target This invention relates generally to the fields of RNA inter cell or tissue, or by restricted entry or trafficking of the com ference, delivery of RNA therapeutics, and to the chemistry of pound within cells. Delivery of a therapeutic material is in lipids. More particularly, this invention relates to composi general restricted by membranes of cells. These barriers and tions and formulations for ribonucleic acids, and their uses for restrictions to delivery can result in the need to use much 35 medicaments and for delivery as therapeutics. This invention higher concentrations of a compound than is desirable to relates generally to methods of using ribonucleic acids in achieve a result, which brings the risk of toxic effects and side RNA interference for gene-specific inhibition of gene expres effects. sion in mammals. One strategy for delivery is to improve transport of a com This invention provides a range of compositions, formula pound into cells using lipid or polymeric carrier molecules. 40 tions and methods which include an interfering nucleic acid These materials can take advantage of mechanisms that exist or a precursor thereof in combination with various compo for selective entry into a cell, while still excluding exogenous nents including lipopeptides, lipids, lipoid moieties, and molecules such as nucleic acids and proteins. For example, a natural or synthetic polymers. cationic lipid may interact with a drug agent and provide In some aspects, this invention provides novel composi contact with a cell membrane. Lipid molecules can also be 45 tions to facilitate the delivery of nucleic acids including organized into liposomes or particles as carriers for drug RNAi-inducing agents, antisense RNA agents, or DNA to agents. Liposomal drug carriers can protect a drug molecule cells, tissues, organs, and in living animals, for example, from degradation while improving its uptake by cells. Also, mammals and humans. liposomal drug carriers can encapsulate or bind certain com Lipopeptides pounds by electrostatic and other interactions, and may inter 50 This invention provides a range of lipopeptides for delivery act with negatively charged cell membranes to initiate trans and administration of interfering-RNA agents or antisense port across a membrane. RNAS. The lipopeptides can be cationic, or non-cationic. As The understanding of regulatory RNA and the develop used herein, non-cationic includes neutral and anionic. Cat ment of RNA interference (RNAi), RNAi therapy, RNA ionic lipopeptides may have one or more cationic sites. based drugs, antisense therapy, and gene therapy, among oth 55 Lipopeptides of this disclosure may be formed by substi ers, has increased the need for effective means of introducing tuting an nucleic acid delivery-enhancing or lipoid group at active nucleic acid the N-terminus or the C-terminus of a peptide, or both termini agents into cells. In general, nucleic acids are stable for of the peptide. In some aspects, the nucleic acid delivery or only limited times in cells or plasma. However, nucleic acid lipoid group may be linked to the alpha-carbon of one or more based agents can be stabilized in compositions and formula 60 an amino acid residues of the peptide or to one or more amine tions which may then be dispersed for cellular delivery. groups, each amine group being adjacent to the alpha-carbon What is needed are compositions and formulations for of an amino acid residue of the peptide, or a combination of intracellular and in vivo delivery of a nucleic acid agent for the N-terminus, C-terminus, alpha-carbon of one or more an use, ultimately, as a therapeutic, which maintain cytoprotec amino acid residues of the peptide or to one or more amine tion and relatively low toxicity. Furthermore, there is a need 65 groups, each amine group being adjacent to the alpha-carbon for compositions and methods to deliver double-stranded of an amino acid residue of the peptide. In some embodi RNA to cells to produce the response of RNA interference. ments, the peptide core may include two or more sequential US 9.220,785 B2 3 4 amino acids, or a peptide of 2 to 100 amino acid residues (or Lipopeptides of this disclosure can be prepared where, for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, example, the central peptide may be Poly-Lys-Trp., 4:1, M. 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32,33, 34,35, 36, 37, 20,000-50,000; Poly-Orn-Trp., 4:1, M20,000-50,000; frag 38,39, 40, 41,42, 43,44, 45,46, 47, 48,49, 50, 51, 52,53,54, ments or variants of mellitin protein, and fragments or vari 55,56, 57,58, 59, 60, 61, 62,63, 64, 65, 66, 67,68, 69,70, 71, ants of a histone protein, e.g., histone H1, histone H2A, 72, 73,74, 75,76, 77,78, 79,80, 81,82, 83, 84,85, 86, 87,88, histone H2B, histone H3 or histone H4.
Load more

Recommended publications
  • Sterols As Dietary Markers for Drosophila Melanogaster
    bioRxiv preprint doi: https://doi.org/10.1101/857664; this version posted November 29, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Sterols as dietary markers for Drosophila melanogaster 2 3 Oskar Knittelfelder1, Elodie Prince2, Susanne Sales1,3, Eric Fritzsche4, Thomas Wöhner4, 4 Marko Brankatschk2, and Andrej Shevchenko1,5 5 6 1MPI of Molecular Cell Biology and Genetics, Pfotenhauerstraße 108, 01307 Dresden, 7 Germany 8 2Biotechnologisches Zentrum, Technische Universität Dresden, Tatzberg 47/49, 01309 9 Dresden, Germany 10 3Present address: Thermo Fischer Scientific GmbH, 63303 Dreieich, Germany 11 4Julius Kühn Institut, Pillnitzer Platz 3a, 01326 Dresden, Germany 12 5corresponding author: [email protected] 13 14 ORCID 15 Oskar Knittelfelder: 0000-0002-1565-7238 16 Marko Brankatschk: 0000-0001-5274-4552 17 Andrej Shevchenko: 0000-0002-5079-1109 18 19 Author contributions 20 Experiments design: OK, EP, MB, AS; methods development: OK, SS; experimental work: 21 OK, EP; materials and reagents: EF, TW; data analysis: OK; data interpretation: OK, EP, MB, 22 AS; manuscript preparation: OK, EP, MB, AS; funding: MB, AS 23 24 25 1 bioRxiv preprint doi: https://doi.org/10.1101/857664; this version posted November 29, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.
    [Show full text]
  • • Our Bodies Make All the Cholesterol We Need. • 85 % of Our Blood
    • Our bodies make all the cholesterol we need. • 85 % of our blood cholesterol level is endogenous • 15 % = dietary from meat, poultry, fish, seafood and dairy products. • It's possible for some people to eat foods high in cholesterol and still have low blood cholesterol levels. • Likewise, it's possible to eat foods low in cholesterol and have a high blood cholesterol level SYNTHESIS OF CHOLESTEROL • LOCATION • All tissues • Liver • Cortex of adrenal gland • Gonads • Smooth endoplasmic reticulum Cholesterol biosynthesis and degradation • Diet: only found in animal fat • Biosynthesis: primarily synthesized in the liver from acetyl-coA; biosynthesis is inhibited by LDL uptake • Degradation: only occurs in the liver • Cholesterol is only synthesized by animals • Although de novo synthesis of cholesterol occurs in/ by almost all tissues in humans, the capacity is greatest in liver, intestine, adrenal cortex, and reproductive tissues, including ovaries, testes, and placenta. • Most de novo synthesis occurs in the liver, where cholesterol is synthesized from acetyl-CoA in the cytoplasm. • Biosynthesis in the liver accounts for approximately 10%, and in the intestines approximately 15%, of the amount produced each day. • Since cholesterol is not synthesized in plants; vegetables & fruits play a major role in low cholesterol diets. • As previously mentioned, cholesterol biosynthesis is necessary for membrane synthesis, and as a precursor for steroid synthesis including steroid hormone and vitamin D production, and bile acid synthesis, in the liver. • Slightly less than half of the cholesterol in the body derives from biosynthesis de novo. • Most cells derive their cholesterol from LDL or HDL, but some cholesterol may be synthesize: de novo.
    [Show full text]
  • Ligands of Therapeutic Utility for the Liver X Receptors
    molecules Review Ligands of Therapeutic Utility for the Liver X Receptors Rajesh Komati, Dominick Spadoni, Shilong Zheng, Jayalakshmi Sridhar, Kevin E. Riley and Guangdi Wang * Department of Chemistry and RCMI Cancer Research Center, Xavier University of Louisiana, New Orleans, LA 70125, USA; [email protected] (R.K.); [email protected] (D.S.); [email protected] (S.Z.); [email protected] (J.S.); [email protected] (K.E.R.) * Correspondence: [email protected] Academic Editor: Derek J. McPhee Received: 31 October 2016; Accepted: 30 December 2016; Published: 5 January 2017 Abstract: Liver X receptors (LXRs) have been increasingly recognized as a potential therapeutic target to treat pathological conditions ranging from vascular and metabolic diseases, neurological degeneration, to cancers that are driven by lipid metabolism. Amidst intensifying efforts to discover ligands that act through LXRs to achieve the sought-after pharmacological outcomes, several lead compounds are already being tested in clinical trials for a variety of disease interventions. While more potent and selective LXR ligands continue to emerge from screening of small molecule libraries, rational design, and empirical medicinal chemistry approaches, challenges remain in minimizing undesirable effects of LXR activation on lipid metabolism. This review provides a summary of known endogenous, naturally occurring, and synthetic ligands. The review also offers considerations from a molecular modeling perspective with which to design more specific LXRβ ligands based on the interaction energies of ligands and the important amino acid residues in the LXRβ ligand binding domain. Keywords: liver X receptors; LXRα; LXRβ specific ligands; atherosclerosis; diabetes; Alzheimer’s disease; cancer; lipid metabolism; molecular modeling; interaction energy 1.
    [Show full text]
  • Genetic Deletion of Abcc6 Disturbs Cholesterol Homeostasis in Mice Bettina Ibold1, Janina Tiemann1, Isabel Faust1, Uta Ceglarek2, Julia Dittrich2, Theo G
    www.nature.com/scientificreports OPEN Genetic deletion of Abcc6 disturbs cholesterol homeostasis in mice Bettina Ibold1, Janina Tiemann1, Isabel Faust1, Uta Ceglarek2, Julia Dittrich2, Theo G. M. F. Gorgels3,4, Arthur A. B. Bergen4,5, Olivier Vanakker6, Matthias Van Gils6, Cornelius Knabbe1 & Doris Hendig1* Genetic studies link adenosine triphosphate-binding cassette transporter C6 (ABCC6) mutations to pseudoxanthoma elasticum (PXE). ABCC6 sequence variations are correlated with altered HDL cholesterol levels and an elevated risk of coronary artery diseases. However, the role of ABCC6 in cholesterol homeostasis is not widely known. Here, we report reduced serum cholesterol and phytosterol levels in Abcc6-defcient mice, indicating an impaired sterol absorption. Ratios of cholesterol precursors to cholesterol were increased, confrmed by upregulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase (Hmgcr) expression, suggesting activation of cholesterol biosynthesis in Abcc6−/− mice. We found that cholesterol depletion was accompanied by a substantial decrease in HDL cholesterol mediated by lowered ApoA-I and ApoA-II protein levels and not by inhibited lecithin-cholesterol transferase activity. Additionally, higher proprotein convertase subtilisin/kexin type 9 (Pcsk9) serum levels in Abcc6−/− mice and PXE patients and elevated ApoB level in knockout mice were observed, suggesting a potentially altered very low-density lipoprotein synthesis. Our results underline the role of Abcc6 in cholesterol homeostasis and indicate impaired cholesterol metabolism as an important pathomechanism involved in PXE manifestation. Mutations in the adenosine triphosphate-binding cassette transporter C6 (ABCC6) gene are responsible for pseudoxanthoma elasticum (PXE), a metabolic disease, hallmarked by a progressive elastic fber calcifcation of the skin, eyes and cardiovascular system.
    [Show full text]
  • Structural Basis for Human Sterol Isomerase in Cholesterol Biosynthesis and Multidrug Recognition
    ARTICLE https://doi.org/10.1038/s41467-019-10279-w OPEN Structural basis for human sterol isomerase in cholesterol biosynthesis and multidrug recognition Tao Long 1, Abdirahman Hassan 1, Bonne M Thompson2, Jeffrey G McDonald1,2, Jiawei Wang3 & Xiaochun Li 1,4 3-β-hydroxysteroid-Δ8, Δ7-isomerase, known as Emopamil-Binding Protein (EBP), is an endoplasmic reticulum membrane protein involved in cholesterol biosynthesis, autophagy, 1234567890():,; oligodendrocyte formation. The mutation on EBP can cause Conradi-Hunermann syndrome, an inborn error. Interestingly, EBP binds an abundance of structurally diverse pharmacolo- gically active compounds, causing drug resistance. Here, we report two crystal structures of human EBP, one in complex with the anti-breast cancer drug tamoxifen and the other in complex with the cholesterol biosynthesis inhibitor U18666A. EBP adopts an unreported fold involving five transmembrane-helices (TMs) that creates a membrane cavity presenting a pharmacological binding site that accommodates multiple different ligands. The compounds exploit their positively-charged amine group to mimic the carbocationic sterol intermediate. Mutagenesis studies on specific residues abolish the isomerase activity and decrease the multidrug binding capacity. This work reveals the catalytic mechanism of EBP-mediated isomerization in cholesterol biosynthesis and how this protein may act as a multi-drug binder. 1 Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 2 Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 3 State Key Laboratory of Membrane Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China. 4 Department of Biophysics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
    [Show full text]
  • Steroidal Triterpenes of Cholesterol Synthesis
    Molecules 2013, 18, 4002-4017; doi:10.3390/molecules18044002 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Review Steroidal Triterpenes of Cholesterol Synthesis Jure Ačimovič and Damjana Rozman * Centre for Functional Genomics and Bio-Chips, Faculty of Medicine, Institute of Biochemistry, University of Ljubljana, Zaloška 4, Ljubljana SI-1000, Slovenia; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +386-1-543-7591; Fax: +386-1-543-7588. Received: 18 February 2013; in revised form: 19 March 2013 / Accepted: 27 March 2013 / Published: 4 April 2013 Abstract: Cholesterol synthesis is a ubiquitous and housekeeping metabolic pathway that leads to cholesterol, an essential structural component of mammalian cell membranes, required for proper membrane permeability and fluidity. The last part of the pathway involves steroidal triterpenes with cholestane ring structures. It starts by conversion of acyclic squalene into lanosterol, the first sterol intermediate of the pathway, followed by production of 20 structurally very similar steroidal triterpene molecules in over 11 complex enzyme reactions. Due to the structural similarities of sterol intermediates and the broad substrate specificity of the enzymes involved (especially sterol-Δ24-reductase; DHCR24) the exact sequence of the reactions between lanosterol and cholesterol remains undefined. This article reviews all hitherto known structures of post-squalene steroidal triterpenes of cholesterol synthesis, their biological roles and the enzymes responsible for their synthesis. Furthermore, it summarises kinetic parameters of enzymes (Vmax and Km) and sterol intermediate concentrations from various tissues. Due to the complexity of the post-squalene cholesterol synthesis pathway, future studies will require a comprehensive meta-analysis of the pathway to elucidate the exact reaction sequence in different tissues, physiological or disease conditions.
    [Show full text]
  • Lipid Maps Mass Spectrometry Methods Chapters
    LIPID MAPS MASS SPECTROMETRY METHODS CHAPTERS DISCLAIMER: These chapters were written for the sole purpose of guiding qualified, professional scientists in the indicated laboratory procedures. Some of the procedures involve the use of chemicals or equipment that may be dangerous, particularly if improperly performed or if carried out by personnel that are not appropriately trained in laboratory procedures. The authors, editors, institutions, publisher, and associated companies have no responsibility whatsoever for any injuries, harm, damage to property or any monetary losses associated with the use of the procedures described in these chapters. The end user accepts all responsibility for use of the procedures described in these chapters. This work is provided on the LIPID MAPS website with the written permission of the Publisher and the entire volume may be viewed from the website http://www.sciencedirect.com/science/bookseries/00766879. CHAPTER ONE Qualitative Analysis and Quantitative Assessment of Changes in Neutral Glycerol Lipid Molecular Species Within Cells Jessica Krank,* Robert C. Murphy,* Robert M. Barkley,* Eva Duchoslav,† and Andrew McAnoy* Contents 1. Introduction 2 2. Reagents 3 2.1. Cell culture 3 2.2. Standards 3 2.3. Extraction and purification 3 3. Methods 4 3.1. Cell culture 4 4. Results 7 4.1. Qualitative analysis 7 4.2. Quantitative analysis 11 5. Conclusions 19 Acknowledgments 19 References 19 Abstract Triacylglycerols (TAGs) and diacylglycerols (DAGs) are present in cells as a complex mixture of molecular species that differ in the nature of the fatty acyl groups esterified to the glycerol backbone. In some cases, the molecular weights of these species are identical, confounding assignments of identity and quantity by molecular weight.
    [Show full text]
  • GRAS Notice (GRN) No. 732 for Docosahexaenoic Acid Oil
    GRAS Notice (GRN) No. 732 https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/default.htm NutLrnSomce, Inc. 6309 Morning Dew 0, Clarksv ijJl e, MD 2 E02.9 (410) -53 E-3336 ox (10 I) 875-6A54 September 18, 2017 l : 'J ') ··~17 ~C.: ;,; i· L ...n Dr. Paulette Gaynor OFFICE OF Office of Food Additive Safety (HFS-200) FOOD ADDITlVE SAFETY Center for Food Safety and Applied Nutrition Food and Drug Administration 5001 Campus Drive College Park, MD 207 40 Subject: GRAS Notice for Docosahexaenoic Acid (DHA)-Rich Oil for Food Applications Dear Dr. Gaynor: On behalf of Linyi Y oukang Biology Co., Ltd., we are submitting a GRAS notification for Docosahexaenoic Acid (DHA)-Rich Oil for general food applications. The attached document contains the specific information that addresses the safe human food uses (infant formulas) for the notified substance. We believe that this determination and notification are in compliance with Pursuant to 21 C.F.R. Part 170, subpart E. We enclose an original copy of this notification for your review. Please feel free to contact me if additional information or clarification is needed as you proceed with the review. We would appreciate your kind attention to this matter. Sincerely, (b) (6) !f/1cf/17 · Susan Cho, Ph.D. Susanscho [email protected] Agent for Linyi Y oukang Biology Co., Ltd. enclosure 1 DHA GRAS for General Food Applications-Expert Panel Report DETERMINATION OF THE GENERALLY RECOGNIZED AS SAFE (GRAS) STATUS OF DOCOSAHEXAENOIC ACID-RICH OIL AS A FOOD INGREDIENT FOR GENERAL FOOD APPLICATIONS Prepared for Linyi Youkang Biology Co., Ltd Prepared by: NutraSource, Inc.
    [Show full text]
  • Sterols Mass Spectra Protocol
    Core J Extraction and Analysis of Cellular Sterol Lipids 11.09.2006 By: E. McCrum, J. McDonald, B.Thompson Synopsis: This protocol describes the standard method for the extraction and analysis of sterols following a LIPID MAPS time course protocol. Cells should be grown and treated according to a LIPID MAPS protocol. Sterols are extracted via a modified Bligh-Dyer method and separated using a reverse phase binary liquid chromatography (LC) gradient. Sterols are quantitated using a MRM method with positive electrospray ionization mass spectrometry (ESI- MS) and normalized to DNA. I. Extraction of Sterol Lipids The extraction protocol outlined below is for cells grown in 60 or 100mm dishes suspended in 2 mL of DPBS. After extraction and quantification of lipids, sterols are normalized to mass of DNA. Reagents Required: Chloroform High purity water DPBS MeOH EDTA A. Lipid Extraction from Medium B. Cell Harvest and Lipid Extraction 1. Remove medium to a 15 mL conical tube. Centrifuge at 2400 rpm for 10 min (eppendorf 5810 R with swinging bucket rotor). Transfer supernatant to a new tube and add 10 μL of each surrogate mix. Store at - 80°C until extraction and analysis. 2. After washing cells twice with 3 mL DPBS, add 2 mL DPBS/1mM EDTA and scrape cells loose from dish surface. 3. Transfer the cells to a 15 mL polypropylene conical tube. Pipette 20 times to suspend cells. 4. Transfer 400 µL to a 1.5 mL eppendorf tube for DNA assay. To these, add 20 µL 50% EtOH in H2O. Store at -80˚C until assay.
    [Show full text]
  • Amino Acid Lipids and Uses Thereof
    (19) & (11) EP 2 494 993 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 05.09.2012 Bulletin 2012/36 A61K 48/00 (2006.01) A61K 47/06 (2006.01) A61K 9/127 (2006.01) C12N 15/88 (2006.01) (2006.01) (2006.01) (21) Application number: 12158867.7 C07C 279/14 C07D 213/40 C07D 233/26 (2006.01) C12N 15/11 (2006.01) (22) Date of filing: 02.05.2008 (84) Designated Contracting States: • Houston, Michael AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Sammamish, WA Washington 98074 (US) HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT • Harvie, Pierrot RO SE SI SK TR Bothell, WA Washington 98011 (US) Designated Extension States: • Adami, Roger AL BA MK RS Bothell, WA Washington 98012 (US) • Fam, Renata (30) Priority: 04.05.2007 US 916131 P Kenmore, WA Washington 98028 (US) 29.06.2007 US 947282 P • Prieve, Mary 02.08.2007 US 953667 P Lake Forest Park, WA Washington 98155 (US) 14.09.2007 US 972590 P • Fosnaugh, Kathy 14.09.2007 US 972653 P Bellevue, WA Washington 98008 (US) 22.01.2008 US 22571 P • Seth, Shaguna Bothell, WA Washington 98012 (US) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: (74) Representative: Srinivasan, Ravi Chandran 08747568.7 / 2 157 982 J A Kemp 14 South Square (71) Applicant: Marina Biotech, Inc. Gray’s Inn Bothell, WA 98021-7266 (US) London WC1R 5JJ (GB) (72) Inventors: Remarks: • Quay, Steven This application was filed on 09-03-2012 as a Woodinville, WA Washington 98072 (US) divisional application to the application mentioned under INID code 62.
    [Show full text]
  • Chromatographic Sterol Analysis As Applied to the Investigation of Milk Fat and Other Oils and Fats
    CHROMATOGRAPHIC STEROL ANALYSIS AS APPLIED TO THE INVESTIGATION OF MILK FAT AND OTHER OILS AND FATS ACADEMISCH PROEFSCHRIFT TER VERKRIJGING VAN DE GRAAD VAN DOCTOR IN DE WISKUNDE EN NATUURWETENSCHAPPEN AAN DE UNIVERSITEIT VAN AMSTERDAM, OP GEZAG VAN DE RECTOR MAGNIFICUS DR. J. KOK, HOOGLERAAR IN DE FACULTEIT DER WISKUNDE EN NATUURWETENSCHAPPEN IN HET OPENBAAR TE VERDEDIGEN IN DE AULA DER UNIVERSITEIT (TIJDELIJK IN DE LUTHERSE KERK, INGANG SINGEL 411, HOEK SPUl) OP WOENSDAG 23 OKTOBER 1963, DES NAMIDDAGS TE 16 UUR DOOR JAN WILLEM COPIUS PEEREBOOM GEBOREN TE 'S-GRAVENHAGE qP CENTRUM VOOR LANDBOUWPUBLIKATIES EN LANDBOUWDOCUMENTATIE WAGENINGEN 1963 1"%-! .••: i PROMOTOR:PROF .DR .W .VA NTONGERE N Es ist nichtgenug zu wissen Manmuss auch anwenden Es ist nichtgenug zu wollen Manmuss auch tun. GOETHE Bij de voltooiing van dit proefschrift betuig ik in de eerste plaats gaarne mijn dank aan alle hoogleraren en lectoren, die tot mijn wetenschappelijke vorming hebben bijgedragen. Hooggeleerde WIBAUT, naar U gaat mijn dank uit voor het inzicht in de organische chemie, dat ik van U mocht ontvangen. Van mijn blijvende belangstelling voor klassieke onderwerpen uit de organische chemie als de sterolchemie, mogen vele gedeelten van dit proefschrift getuigen. Hooggeleerde VAN TONGEREN, Hooggeschatte Promotor, met gevoelens van grote erkentelijkheid richt ik mij tot U om dank te zeggen voor het onderricht in de ana­ lytische chemie en voor de grote steun, die ik bij de bewerking van dit proefschrift van U mocht ondervinden. Het geduld waarmede U steeds weer talloze onvolkomen­ heden in de Engelse tekst signaleerde, heeft mijn grote bewondering. Het onderzoek werd in zijn geheel uitgevoerd op het RIJKSZUIVELSTATION.
    [Show full text]
  • Simplified LC-MS Method for Analysis of Sterols in Biological Samples
    molecules Article Simplified LC-MS Method for Analysis of Sterols in Biological Samples Cene Skubic 1, Irena Vovk 2, Damjana Rozman 1 and Mitja Križman 2,* 1 Center for Functional Genomics and Bio-Chips, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Zaloška cesta 4, SI-1000 Ljubljana, Slovenia; [email protected] (C.S.); [email protected] (D.R.) 2 Department of Food Chemistry, National Institute of Chemistry, Ljubljana, Hajdrihova 19, SI-1000 Ljubljana, Slovenia; [email protected] * Correspondence: [email protected]; Tel./Fax: +386-1-4760-266 Academic Editors: Vassilios Roussis and Efstathia Ioannou Received: 13 August 2020; Accepted: 8 September 2020; Published: 9 September 2020 Abstract: We developed a simple and robust liquid chromatographic/mass spectrometric method (LC-MS) for the quantitative analysis of 10 sterols from the late part of cholesterol synthesis (zymosterol, dehydrolathosterol, 7-dehydrodesmosterol, desmosterol, zymostenol, lathosterol, FFMAS, TMAS, lanosterol, and dihydrolanosterol) from cultured human hepatocytes in a single chromatographic run using a pentafluorophenyl (PFP) stationary phase. The method also avails on a minimized sample preparation procedure in order to obtain a relatively high sample throughput. The method was validated on 10 sterol standards that were detected in a single chromatographic LC-MS run without derivatization. Our developed method can be used in research or clinical applications for disease-related detection of accumulated cholesterol intermediates. Disorders in the late part of cholesterol synthesis lead to severe malformation in human patients. The developed method enables a simple, sensitive, and fast quantification of sterols, without the need of extended knowledge of the LC-MS technique, and represents a new analytical tool in the rising field of cholesterolomics.
    [Show full text]